{"transactions":[{"id":4616594,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-09-14T12:30:06.000Z","date":"2026-09-14","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the third tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount includes 208 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026."}],"balance_after":508279,"source":{"system":"sec-edgar","filing":"0001193125-26-389889","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526389889/ownership.xml","form_type":"4"}},{"id":689331,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-08-12T12:30:06.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the second tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":383071,"source":{"system":"sec-edgar","filing":"0001193125-26-345837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526345837/ownership.xml","form_type":"4"}},{"id":725574,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-06-26T20:30:10.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":13008,"price":45.03,"value":585750.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."}],"balance_after":320571,"source":{"system":"sec-edgar","filing":"0001193125-26-285567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526285567/ownership.xml","form_type":"4"}},{"id":730571,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-06-22T13:45:04.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares represent the first tranche of performance share units granted effective March 12, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 12, 2028. Each performance\nshare unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement."}],"balance_after":333579,"source":{"system":"sec-edgar","filing":"0001193125-26-276879","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526276879/ownership.xml","form_type":"4"}},{"id":827417,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-03-26T22:42:48.000Z","date":"2026-03-25","kind":"sale","planned":true,"acquired":false,"shares":10702,"price":18.47,"value":197665.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2026 at prices ranging from $18.36 to $18.80. The Reporting Person undertakes to provide the Issuer, any security holder of\nthe Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount includes 793 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan."}],"balance_after":271079,"source":{"system":"sec-edgar","filing":"0001193125-26-126827","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526126827/ownership.xml","form_type":"4"}},{"id":917824,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2026-02-05T21:55:45.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":407576,"source":{"system":"sec-edgar","filing":"0001193125-26-039579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526039579/ownership.xml","form_type":"4"}},{"id":958269,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-12-29T22:00:03.000Z","date":"2025-12-26","kind":"sale","planned":true,"acquired":false,"shares":11276,"price":13.1469,"value":148244.4444,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2025 at prices ranging from $13.02 to $13.33. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":282576,"source":{"system":"sec-edgar","filing":"0001193125-25-335481","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312525335481/ownership.xml","form_type":"4"}},{"id":1031772,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-09-26T21:35:36.000Z","date":"2025-09-25","kind":"sale","planned":true,"acquired":false,"shares":11278,"price":9.77,"value":110186.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."}],"balance_after":293852,"source":{"system":"sec-edgar","filing":"0001193125-25-220848","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312525220848/ownership.xml","form_type":"4"}},{"id":1101109,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-06-26T20:30:09.000Z","date":"2025-06-25","kind":"sale","planned":true,"acquired":false,"shares":11491,"price":6.8,"value":78138.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2025 at prices ranging from $6.67 to $7.03. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":305130,"source":{"system":"sec-edgar","filing":"0000950170-25-090431","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025090431/ownership.xml","form_type":"4"}},{"id":1191011,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-03-26T21:00:13.000Z","date":"2025-03-25","kind":"sale","planned":true,"acquired":false,"shares":6576,"price":6.74,"value":44322.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2025 at prices ranging from $6.67 to $6.79. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":316621,"source":{"system":"sec-edgar","filing":"0000950170-25-045394","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025045394/ownership.xml","form_type":"4"}},{"id":1207873,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2025-03-13T20:30:09.000Z","date":"2025-03-12","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":323197,"source":{"system":"sec-edgar","filing":"0000950170-25-038798","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025038798/ownership.xml","form_type":"4"}},{"id":1321004,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2024-12-27T21:30:16.000Z","date":"2024-12-26","kind":"sale","planned":true,"acquired":false,"shares":4519,"price":7.43,"value":33576.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on December 26, 2024 at prices ranging from $6.98 to $7.66. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":173197,"source":{"system":"sec-edgar","filing":"0001104659-24-132160","document":"tm2432133-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000110465924132160/tm2432133-1_4seq1.xml","form_type":"4"}},{"id":1399509,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2024-09-26T00:28:35.000Z","date":"2024-09-25","kind":"sale","planned":true,"acquired":false,"shares":4430,"price":5.98,"value":26491.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2024 at prices ranging from $5.95 to $6.07. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":177716,"source":{"system":"sec-edgar","filing":"0000950170-24-109447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024109447/ownership.xml","form_type":"4"}},{"id":1469590,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2024-06-25T23:00:03.000Z","date":"2024-06-25","kind":"sale","planned":true,"acquired":false,"shares":17854,"price":7.22,"value":128905.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on March 14, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average sales price. These shares were sold in multiple transactions on June 25, 2024 at prices ranging from $7.20 to $7.26. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":182146,"source":{"system":"sec-edgar","filing":"0000950170-24-077497","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024077497/ownership.xml","form_type":"4"}},{"id":1610173,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-29T21:45:38.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest and become exercisable in 48 equal monthly installments, with the first installment vesting on March 27, 2024, subject to the Reporting Person providing continuous service to the Issuer as of each such vesting date."}],"balance_after":125000,"derivative":{"exercise_price":4.98,"expiration_date":"2034-02-26","underlying":"Common Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000950170-24-023201","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024023201/ownership.xml","form_type":"4"}},{"id":1919665,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Shares","published_at":"2023-04-14T20:45:43.000Z","date":"2023-04-13","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer, with 25% of the RSUs vesting on April 13, 2024, and the remaining RSUs vesting in 12 equal quarterly installments over the subsequent three years thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0001209191-23-024335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000120919123024335/doc4.xml","form_type":"4"}},{"id":1968954,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2023-03-06T20:46:40.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":44879,"price":0.587,"value":26343.973,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above."}],"balance_after":378651,"source":{"system":"sec-edgar","filing":"0001485003-23-000111","document":"wf-form4_167815358414793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000111/wf-form4_167815358414793.xml","form_type":"4"}},{"id":1968953,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2023-03-06T20:46:40.000Z","date":"2023-03-02","kind":"exercise","acquired":true,"shares":113175,"price":0.587,"value":66433.725,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents performance-based restricted stock units granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc."}],"balance_after":423530,"source":{"system":"sec-edgar","filing":"0001485003-23-000111","document":"wf-form4_167815358414793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000111/wf-form4_167815358414793.xml","form_type":"4"}},{"id":1968952,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2023-03-06T20:46:40.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":73361,"price":0.587,"value":43062.907,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a performance-based restricted stock unit award granted on October 21, 2021. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above."}],"balance_after":310355,"source":{"system":"sec-edgar","filing":"0001485003-23-000111","document":"wf-form4_167815358414793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000111/wf-form4_167815358414793.xml","form_type":"4"}},{"id":1968951,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2023-03-06T20:46:40.000Z","date":"2023-03-02","kind":"exercise","acquired":true,"shares":185000,"price":0.587,"value":108595.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents performance-based restricted stock units granted on October 1, 2021, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc."}],"balance_after":383716,"source":{"system":"sec-edgar","filing":"0001485003-23-000111","document":"wf-form4_167815358414793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000111/wf-form4_167815358414793.xml","form_type":"4"}},{"id":1968950,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2023-03-06T20:46:40.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":100978,"price":0.587,"value":59274.086,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the prices set forth above."}],"balance_after":198716,"source":{"system":"sec-edgar","filing":"0001485003-23-000111","document":"wf-form4_167815358414793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000111/wf-form4_167815358414793.xml","form_type":"4"}},{"id":1995826,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2023-02-23T19:38:14.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":39831,"price":0.5873,"value":23392.7463,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the price set forth above."}],"balance_after":299694,"source":{"system":"sec-edgar","filing":"0001485003-23-000066","document":"wf-form4_167719907774834.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000066/wf-form4_167719907774834.xml","form_type":"4"}},{"id":2378476,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Common Stock","published_at":"2022-02-23T20:37:44.000Z","date":"2022-02-18","kind":"grant","acquired":true,"shares":339525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") which shall vest annually in equal amounts over a four-year period following the grant date, so long as the reporting person remains employed by Sesen Bio, Inc. (the \"Company\"). Each RSU represents a contingent right to receive one share of the Company's common stock. The compensation committee of the Company approved the grant to the reporting person, based on market analysis by Radford of public, pre-commercial and commercial biopharmaceutical companies."}],"balance_after":339525,"source":{"system":"sec-edgar","filing":"0001485003-22-000022","document":"wf-form4_164566664903724.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500322000022/wf-form4_164566664903724.xml","form_type":"4"}},{"id":2839206,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-02-23T17:18:28.000Z","date":"2021-02-19","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 19, 2021, the reporting person was awarded options to purchase 300,000 shares of the common stock of Sesen Bio, Inc. (the \"Company\"), which options vest 6.25% every three months commencing on January 1, 2021 over four years provided the reporting person is employed by the Company at each such vesting date."}],"balance_after":300000,"derivative":{"exercise_price":3.17,"expiration_date":"2031-02-19","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001485003-21-000026","document":"wf-form4_161411868889400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500321000026/wf-form4_161411868889400.xml","form_type":"4"}},{"id":3266750,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-02-18T16:57:28.000Z","date":"2020-02-13","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 13, 2020, the reporting person was awarded options to purchase 260,000 shares of the common stock of Sesen Bio, Inc. (the \"Company\"), which options vest 6.25% every three months over four years provided the reporting person is employed by the Company at each such vesting date."}],"balance_after":260000,"derivative":{"exercise_price":0.8911,"expiration_date":"2030-02-13","underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001485003-20-000012","document":"wf-form4_158206303194870.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500320000012/wf-form4_158206303194870.xml","form_type":"4"}},{"id":3447095,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":24156,"kind":"person","name":"Sullivan Mark","position":1,"cik":"0001331843","reported_name":"Sullivan Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel & Secretary"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-08-05T21:34:03.000Z","date":"2019-08-01","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On August 1, 2019, the reporting person was granted an option to purchase 200,000 shares of the common stock of Sesen Bio, Inc. (the \"Company\"), which option vests 6.25% every three months over four years provided the reporting person is employed by the Company at each such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":1.16,"expiration_date":"2029-08-01","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001485003-19-000053","document":"wf-form4_156505522499089.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000148500319000053/wf-form4_156505522499089.xml","form_type":"4"}}]}